GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases
GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases. The collaboration...